+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting Anti-HIV Drugs Market - Global Forecast 2026-2032- Product Image
Long-acting Anti-HIV Drugs Market - Global Forecast 2026-2032- Product Image
New

Long-acting Anti-HIV Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118869
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The long-acting anti-HIV drugs market is experiencing rapid transformation, driven by innovation in drug delivery, evolving regulatory landscapes, and operational shifts that optimize adherence and expand access options for patients worldwide.

Market Snapshot: Long-acting Anti-HIV Drugs Market Growth

The Long-acting Anti-HIV Drugs Market grew from USD 376.86 million in 2025 to USD 445.10 million in 2026. It is expected to continue growing at a CAGR of 20.43%, reaching USD 1.38 billion by 2032. This robust momentum underscores accelerating adoption of injectables, implants, and extended-release technologies as pharmaceutical developers, healthcare providers, and payers recalibrate to meet evolving patient and health system needs.

Scope & Segmentation of the Long-acting Anti-HIV Drugs Market

This report provides a comprehensive analysis of core market segments shaping the future of long-acting anti-HIV drugs:

  • Product Types: Focus on long-acting injectables and subcutaneous or intradermal implants, including both biodegradable and non-biodegradable solutions.
  • Mechanisms of Action: Examination of integrase inhibitors, protease inhibitors, and non-nucleoside reverse transcriptase inhibitors adapted for sustained release platforms.
  • Therapy Focus: Detailed review of prevention and treatment settings, highlighting different deployment and monitoring needs.
  • Dosing Frequency: Coverage of monthly, bi-monthly, and quarterly dosing intervals, examining operational impact on patient flow and clinic resource allocation.
  • Distribution Channels: Assessment of hospital pharmacy, retail pharmacy, and online pharmacy models supporting access and adherence.
  • Patient Demographics: Segmentation by adult and pediatric populations, addressing formulation-specific requirements and safety profiles.
  • Regimen Structure: Analysis of fixed-dose combinations, two-drug, and three-drug strategies for both monotherapy and combination regimens.
  • Regional Analysis: Review of dynamics across the Americas, EMEA, and Asia-Pacific, including capacity-building efforts and regulatory variations.

Key Takeaways for Senior Decision-Makers

  • Recent clinical validation and regulatory approvals signal a maturing landscape, giving stakeholders the confidence to scale long-acting modalities into broader clinical practice.
  • Advances in drug formulation, such as polymer-based depots and next-generation implants, enable less frequent dosing and adaptability for diverse patient preferences.
  • Evolving delivery formats are driving new commercial and care models, highlighting the importance of supply chain resilience and last-mile distribution optimization—especially in regions facing logistics hurdles.
  • Regulatory bodies are actively adapting review processes to support rapid access while maintaining robust safety surveillance, influencing development pathways and post-approval studies.
  • Paying attention to mode of distribution—hospital, online, or retail—proves critical for maximizing adherence while minimizing barriers to patient engagement and ongoing care.
  • Growth in the market is tightly linked to the ability to align clinical, commercial, and operational strategies for distinct regional and population-based needs.

Tariff Impact: Navigating Trade and Manufacturing Challenges

The 2025 implementation of cumulative tariffs and revised trade measures has introduced cost pressures affecting procurement, global distribution, and manufacturing localization of long-acting anti-HIV therapies. As a result, industry players are strategically investing in regional manufacturing, dual sourcing, and inventory optimization to strengthen supply chain resilience. These shifts also foster technology transfers and collaborations with local manufacturers, positioning the sector to balance short-term trade challenges with long-term access goals. Enhanced logistical agility—particularly for cold chain and packaging—remains a priority to avoid cost leakages and maintain delivery integrity.

Methodology & Data Sources

This report utilizes a rigorous mixed-methods approach, combining primary expert interviews, regulatory document review, and targeted secondary analysis. Insights are drawn from clinical investigators, supply chain leaders, health policy stakeholders, and technical formulation research to ensure a balanced, actionable perspective.

Why This Report Matters to Market Leaders

  • Gain visibility into the intersecting clinical, regulatory, and operational trends shaping strategy and investment across the long-acting anti-HIV drugs industry.
  • Identify actionable opportunities for product development, portfolio expansion, and partnership—especially in light of new tariff environments and evolving regional adoption.

Conclusion: Strategic Imperatives for Success

As the long-acting anti-HIV drug market evolves, senior leaders are positioned to capitalize on innovation by aligning clinical benefits with robust access strategies. Proactive collaboration, investment in supply chain resilience, and tailored delivery models will be key to unlocking broader therapeutic impact and sustainable growth.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of injectable cabotegravir approvals for pre-exposure prophylaxis in high risk populations
5.2. Advancements in ultra-long acting antiretroviral implants offering quarterly dosing options
5.3. Integration of digital adherence monitoring with long-acting HIV therapy to enhance patient outcomes
5.4. Strategic partnerships between biotech firms and government agencies for decentralized delivery models
5.5. Emergence of subcutaneous injectable antiretroviral combinations targeting virologically suppressed patients
5.6. Pipeline innovation in broadly neutralizing antibody therapies for sustained HIV viral control
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Long-acting Anti-HIV Drugs Market, by Product Type
8.1. Introduction
8.2. Implant
8.2.1. Biodegradable
8.2.2. Non-Biodegradable
8.3. Injectable
8.3.1. Intramuscular
8.3.2. Subcutaneous
9. Long-acting Anti-HIV Drugs Market, by Mode Of Action
9.1. Introduction
9.2. Integrase Inhibitor
9.3. Protease Inhibitor
9.4. Reverse Transcriptase Inhibitor
10. Long-acting Anti-HIV Drugs Market, by Therapy Area
10.1. Introduction
10.2. Prevention
10.3. Treatment
11. Long-acting Anti-HIV Drugs Market, by Dosing Frequency
11.1. Introduction
11.2. Bi-Monthly
11.3. Monthly
11.4. Quarterly
12. Long-acting Anti-HIV Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Long-acting Anti-HIV Drugs Market, by Patient Type
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Long-acting Anti-HIV Drugs Market, by Treatment Regimen
14.1. Introduction
14.2. Combination
14.2.1. Three Drug Regimen
14.2.2. Two Drug Regimen
14.3. Monotherapy
15. Americas Long-acting Anti-HIV Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Long-acting Anti-HIV Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Long-acting Anti-HIV Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. ViiV Healthcare Limited
18.3.2. Gilead Sciences, Inc.
18.3.3. Janssen Pharmaceuticals, Inc.
18.3.4. Merck & Co., Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. LONG-ACTING ANTI-HIV DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 18. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. LONG-ACTING ANTI-HIV DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. LONG-ACTING ANTI-HIV DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. LONG-ACTING ANTI-HIV DRUGS MARKET: RESEARCHAI
FIGURE 30. LONG-ACTING ANTI-HIV DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. LONG-ACTING ANTI-HIV DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. LONG-ACTING ANTI-HIV DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LONG-ACTING ANTI-HIV DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY NON-BIODEGRADABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY NON-BIODEGRADABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTEGRASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INTEGRASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PREVENTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PREVENTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BI-MONTHLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY BI-MONTHLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONTHLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONTHLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY QUARTERLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY QUARTERLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THREE DRUG REGIMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THREE DRUG REGIMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TWO DRUG REGIMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TWO DRUG REGIMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 120. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 121. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 122. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 123. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 124. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 125. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 126. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 127. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 128. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 129. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 130. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 131. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 136. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 137. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 142. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 143. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 144. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 148. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 149. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 154. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 155. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 156. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 157. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 158. MEXICO LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 241. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 244. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 245. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 246. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 247. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 248. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 249. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 250. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 251. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 252. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 253. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 258. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 259. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 260. GERMANY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 261. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 264. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 265. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 266. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 267. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 268. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 269. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 270. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 271. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 272. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 273. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 276. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 277. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 278. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 279. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 280. FRANCE LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 301. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 302. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 303. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2018-2024 (USD MILLION)
TABLE 304. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY IMPLANT, 2025-2030 (USD MILLION)
TABLE 305. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 306. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 307. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
TABLE 308. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY MODE OF ACTION, 2025-2030 (USD MILLION)
TABLE 309. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 310. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 311. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2018-2024 (USD MILLION)
TABLE 312. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DOSING FREQUENCY, 2025-2030 (USD MILLION)
TABLE 313. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 316. ITALY LONG-ACTING ANTI-HIV DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 317

Companies Mentioned

  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Viatris Inc.
  • ViiV Healthcare Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 445.1 Million
Forecasted Market Value ( USD ) by 2032 $ 1380 Million
Compound Annual Growth Rate20.4%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

HIV Drugs Market Report 2025 - Product Image

HIV Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
North America HIV Drugs Market Size, Share, Trends and Forecast by Drug Class, Distribution Channel, and Country, 2025-2033 - Product Image

North America HIV Drugs Market Size, Share, Trends and Forecast by Drug Class, Distribution Channel, and Country, 2025-2033

  • Report
  • 122 Pages
  • North America
From
HIV Drugs - Global Strategic Business Report - Product Image

HIV Drugs - Global Strategic Business Report

  • Report
  • 295 Pages
  • Global
From
Anti-Retroviral Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-Retroviral Drugs Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Injectable HIV Treatment Market - Global Forecast 2026-2032 - Product Image

Injectable HIV Treatment Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.